Metanx® Safety Profile for Healthcare Professionals

Metanx^® is well tolerated in short-term and chronic use.^5,7,9,13

• Side effects and/or discontinuation rates similar to placebo.⁵
• Metanx^® is NOT associated with significant adverse effects such as:
  • Weight gain
  • Blurred vision
  • Dizziness
  • Nausea

Low Potential for Drug Interactions

• Pyridoxal 5'-phosphate should not be given to patients receiving the drug levodopa, because the action of levodopa is antagonized by pyridoxal 5'-phosphate. However, pyridoxal 5'-phosphate may be used concurrently in patients receiving a preparation containing both carbidopa and levodopa. While the concurrent use of phenytoin and folic acid may result in decreased phenytoin effectiveness, no such decreased effectiveness has been reported with the use of L-methylfolate.

For complete prescribing information, view the Metanx^® Package Insert.